Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,415 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF, Witjes JA, Gschwend JE, et al. · N Engl J Med · 2021Clinical Trial, Phase III, Comparative Study
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Apolo AB, Ballman KV, Sonpavde G, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, et al. · N Engl J Med · 2023Comparative Study, Randomized Controlled Trial
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, et al. · N Engl J Med · 2023Clinical Trial, Phase III, Comparative Study
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
Powles TB, Van der Heijden MS, Loriot Y, et al. · Ann Oncol · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Galsky MD, Witjes JA, Gschwend JE, et al. · J Clin Oncol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
Gazzoni G, Michelon I, Vilbert M, et al. · Urol Oncol · 2025Systematic Review, Meta-Analysis
- Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Yajima S, Hirose K, Masuda H · JAMA Netw Open · 2025Systematic Review, Network Meta-Analysis
- Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Powles T, Tagawa S, Vulsteke C, et al. · Ann Oncol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE, Powles T, Sonpavde GP, et al. · Ann Oncol · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Zhang W, Wu H, Wang L, et al. · JAMA Netw Open · 2026Systematic Review, Network Meta-Analysis
- Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
Liu H, Chen J, Huang Y, et al. · Int J Surg · 2024Systematic Review, Meta-Analysis
- Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Galsky MD, Gschwend JE, Milowsky MI, et al. · Ann Oncol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
Wu J, Lin Y, Yang K, et al. · Mol Cancer · 2024Randomized Controlled Trial, Multicenter Study
- Clear Cell Urothelial Carcinoma.
Mai KT, Bateman J, Djordjevic B, et al. · Int J Surg Pathol · 2017Meta-Analysis
- The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang Y, Chen J, Liu H, et al. · Cancer Treat Rev · 2024Systematic Review, Meta-Analysis
- Erdafitinib for advanced urothelial carcinoma.
Burki TK · Lancet Oncol · 2019Clinical Trial, Phase II
- Progress in the treatment of urethral adenocarcinoma.
Guo J, Liang X, Zheng Y, et al. · J Cancer Res Clin Oncol · 2023Systematic Review
- Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
Galsky MD, van der Heijden MS, Powles T, et al. · Eur Urol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
Powles T, Chang YH, Yamamoto Y, et al. · Nat Med · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM, Necchi A, Loriot Y, et al. · Eur Urol Oncol · 2018Research Support, N.I.H., Extramural, Systematic Review
- Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.
Zalay O, Yan M, Sigurdson S, et al. · Curr Oncol · 2022Meta-Analysis, Systematic Review
- Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis.
Sayyid RK, Bernardino R, Chavarriaga J, et al. · World J Urol · 2024Systematic Review, Meta-Analysis
- Folate Intake and Risk of Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Epidemiological Studies.
Gu Y, Zeng J, Zou Y, et al. · Nutr Cancer · 2022Meta-Analysis, Systematic Review
- Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
Bellmunt J, Powles T, Park SH, et al. · Eur Urol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.